A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?

被引：0

作者：

Paolo Antonetti

Maria Concetta Fargnoli

Giampiero Porzio

Lisa Salvatore

Roberto Filippi

Michele Ghidini

Olga Nigro

Fabio Gelsomino

Ina Valeria Zurlo

Emanuela Dell’Aquila

Pasquale Lombardi

Susana Roselló Keränen

Ilaria Depetris

Riccardo Giampieri

Cristina Morelli

Michele De Tursi

Francesca Romana Di Pietro

Nicoletta Zanaletti

Pasquale Vitale

Ingrid Garajova

Gian Paolo Spinelli

Federica Zoratto

Michela Roberto

Angelica Petrillo

Giacomo Aimar

Alessio Cortellini

Maria Vittoria Pensieri

Corrado Ficorella

Claudio Ferri

Alessandro Parisi

机构：

[1] Dermatology,Department of Biotechnological and Applied Clinical Sciences

[2] St. Salvatore Hospital,Medical Oncology, Comprehensive Cancer Center

[3] University of L’Aquila,Department of Oncology

[4] Medical Oncology,Centro Oncologico Ematologico Subalpino

[5] St. Salvatore Hospital,Department of Oncology and Hematology

[6] Università Cattolica del Sacro Cuore,Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute

[7] Fondazione Policlinico Universitario Agostino Gemelli,Clinica Oncologica e Centro Regionale di Genetica Oncologica

[8] IRCCS,Medical Oncology Unit and PhD program in Systems and Experimental Medicine (XXXV cycle)

[9] University of Turin,Department of Medical, Oral and Biotechnological Sciences and Center for Advance Studies and Technology (CAST)

[10] Division of Medical Oncology,Department of Precision Medicine

[11] Candiolo Cancer Institute,Department of Clinical and Molecular Medicine

[12] FPO – IRCCS,Department of Life, Health and Environmental Sciences

[13] Azienda Universitaria Ospedaliera Città della Salute e della Scienza di Torino,undefined

[14] Medical Oncology Unit,undefined

[15] Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico,undefined

[16] Medical Oncology,undefined

[17] ASST Sette Laghi,undefined

[18] Ospedale di Circolo e Fondazione Macchi,undefined

[19] Division of Oncology,undefined

[20] University Hospital of Modena,undefined

[21] Medical Oncology,undefined

[22] “Vito Fazzi” Hospital,undefined

[23] Medical Oncology 1,undefined

[24] IRCCS Regina Elena National Cancer Institute,undefined

[25] University of Valencia,undefined

[26] CIBERONC,undefined

[27] Instituto de Salud Carlos III,undefined

[28] Medical Oncology,undefined

[29] ASL TO4,undefined

[30] Ospedale Civile di Ivrea,undefined

[31] Università Politecnica delle Marche,undefined

[32] AOU Ospedali Riuniti,undefined

[33] Tor Vergata University Hospital,undefined

[34] G. D’Annunzio University,undefined

[35] Clinical Oncology Unit,undefined

[36] S.S. Annunziata Hospital,undefined

[37] IRCCS Istituto Dermopatico dell’Immacolata (IDI),undefined

[38] Experimental Clinical Abdominal Oncology Unit,undefined

[39] Istituto Nazionale Tumori-IRCCS-Fondazione G.Pascale,undefined

[40] Università della Campania “Luigi Vanvitelli”,undefined

[41] Medical Oncology Unit,undefined

[42] Santa Chiara Hospital,undefined

[43] Medical Oncology Unit,undefined

[44] University Hospital of Parma,undefined

[45] UOC Territorial Oncology - AUSL Latina-CdS Aprilia – University of Rome “Sapienza”,undefined

[46] Medical Oncology,undefined

[47] Santa Maria Goretti Hospital,undefined

[48] Sapienza University of Rome,undefined

[49] Oncology Unit,undefined

[50] Sant’Andrea Hospital,undefined

来源：

Supportive Care in Cancer | 2022年 / 30卷

关键词：

mCRC; Acneiform rash; Pre-emptive; Reactive; Paronychia; Panitumumab; Cetuximab; Anti-EGFR;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：2455 / 2465

页数：10

共 50 条

[1] A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
Antonetti, Paolo
Fargnoli, Maria Concetta
Porzio, Giampiero
Salvatore, Lisa
Filippi, Roberto
Ghidini, Michele
Nigro, Olga
Gelsomino, Fabio
Zurlo, Ina Valeria
Dell'Aquila, Emanuela
Lombardi, Pasquale
Rosello Keranen, Susana
Depetris, Ilaria
Giampieri, Riccardo
Morelli, Cristina
De Tursi, Michele
Di Pietro, Francesca Romana
Zanaletti, Nicoletta
Vitale, Pasquale
Garajova, Ingrid
Spinelli, Gian Paolo
Zoratto, Federica
Roberto, Michela
Petrillo, Angelica
Aimar, Giacomo
Cortellini, Alessio
Pensieri, Maria Vittoria
Ficorella, Corrado
Ferri, Claudio
Parisi, Alessandro
SUPPORTIVE CARE IN CANCER, 2022, 30 (03) : 2455 - 2465
[2] Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
Parisi, Alessandro
Cortellini, Alessio
Venditti, Olga
Filippi, Roberto
Salvatore, Lisa
Tortora, Giampaolo
Ghidini, Michele
Nigro, Olga
Gelsomino, Fabio
Zurlo, Ina Valeria
Fulgenzi, Claudia
Lombardi, Pasquale
Keraenen, Susana Rosello
Depetris, Ilaria
Giampieri, Riccardo
Morelli, Cristina
Di Marino, Pietro
Di Pietro, Francesca Romana
Zanaletti, Nicoletta
Vitale, Pasquale
Garajova, Ingrid
Spinelli, Gian Paolo
Zoratto, Federica
Roberto, Michela
Petrillo, Angelica
Aimar, Giacomo
Patruno, Leonardo
D'Orazio, Carla
Ficorella, Corrado
Ferri, Claudio
Porzio, Giampiero
FRONTIERS IN ONCOLOGY, 2021, 11
[3] Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study
Fuca, Giovanni
Raimondi, Alessandra
Prisciandaro, Michele
Lonardi, Sara
Cremolini, Chiara
Ratti, Margherita
Clavarezza, Matteo
Murialdo, Roberto
Sartore-Bianchi, Andrea
Smiroldo, Valeria
Berenato, Rosa
Racca, Patrizia
Bergamo, Francesca
Corallo, Salvatore
Di Bartolomeo, Maria
de Braud, Filippo
Morano, Federica
Pietrantonio, Filippo
ONCOLOGIST, 2022, 27 (01) : E29 - E36
[4] Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer
Wang, Chongkai
Sandhu, Jaideep
Fakih, Marwan
ONCOLOGIST, 2022, 27 (02) : 104 - 109
[5] First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy?
Airoldi, Marco
Bartolini, Michela
Fazio, Roberta
Farinatti, Sara
Dapra, Valentina
Santoro, Armando
Puccini, Alberto
CURRENT ONCOLOGY REPORTS, 2024, 26 (11) : 1489 - 1501
[6] Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study
Parisi, Alessandro
Porzio, Giampiero
Cannita, Katia
Venditti, Olga
Avallone, Antonio
Filippi, Roberto
Salvatore, Lisa
Tortora, Giampaolo
Ribelli, Marta
Nigro, Olga
Gelsomino, Fabio
Spallanzani, Andrea
Zurlo, Valeria
Leo, Silvana
Dell'Aquila, Emanuela
Claudia, Fulgenzi
Lombardi, Pasquale
Keranen, Susana Rosello
Aimar, Giacomo
Depetris, Ilaria
Giampieri, Riccardo
Morelli, Cristina
De Tursi, Michele
Tinari, Nicola
Di Pietro, Francesca Romana
De Galitiis, Federica
Zanaletti, Nicoletta
Troiani, Teresa
Vitale, Pasquale
Garajova, Ingrid
Ghidini, Michele
Spinelli, Gian Paolo
Zoratto, Federica
Roberto, Michela
Ierino, Debora
Petrillo, Angelica
D'Orazio, Carla
Ficorella, Corrado
Cortellini, Alessio
CLINICAL COLORECTAL CANCER, 2021, 20 (04) : 318 - 325
[7] The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy
Cai, Changjing
Luo, Qingqing
Liu, Yihan
Peng, Yinghui
Zhang, Xiangyang
Jiang, Zhaohui
Feng, Ziyang
Qi, Yaru
Gao, Yan
Liu, Yongting
Liu, Ping
Chen, Yihong
Guo, Cao
Shen, Hong
Zeng, Shan
Han, Ying
FRONTIERS IN PHARMACOLOGY, 2022, 13
[8] Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy
Randon, Giovanni
Maddalena, Giulia
Germani, Marco Maria
Pircher, Chiara Carlotta
Manca, Paolo
Bergamo, Francesca
Giordano, Mirella
Sposetti, Caterina
Montagna, Aldo
Vetere, Guglielmo
Zambelli, Luca
Rasola, Cosimo
Boccaccino, Alessandra
Pagani, Filippo
Ambrosini, Margherita
Massafra, Marco
Fontanini, Gabriella
Milione, Massimo
Fassan, Matteo
Cremolini, Chiara
Lonardi, Sara
Pietrantonio, Filippo
JCO PRECISION ONCOLOGY, 2022, 6
[9] Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer
Han, Jiaqi
Xiao, Desheng
Tan, Chongqing
Zeng, Xiaohui
Hu, Huabin
Zeng, Shan
Jiang, Qin
She, Longjiang
Yao, Linli
Li, Li
Tang, Lanhua
Ma, Jian
Huang, Jin
Shen, Liangfang
CANCER CONTROL, 2020, 27 (01)
[10] Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study
Parisi, Alessandro
Cortellini, Alessio
Cannita, Katia
Venditti, Olga
Camarda, Floriana
Calegari, Maria Alessandra
Salvatore, Lisa
Tortora, Giampaolo
Rossini, Daniele
Germani, Marco Maria
Boccaccino, Alessandra
Dell'Aquila, Emanuela
Fulgenzi, Claudia
Santini, Daniele
De Tursi, Michele
Tinari, Nicola
Di Marino, Pietro
Lombardi, Pasquale
Rosello Keranen, Susana
Huerta Alvaro, Marisol
Zurlo, Ina Valeria
Corsi, Domenico Cristiano
Emiliani, Alessandra
Zanaletti, Nicoletta
Troiani, Teresa
Vitale, Pasquale
Giampieri, Riccardo
Merloni, Filippo
Occhipinti, Mario Alberto
Marchetti, Paolo
Roberto, Michela
Mazzuca, Federica
Ghidini, Michele
Indini, Alice
Garajova, Ingrid
Zoratto, Federica
Delle Monache, Simona
Porzio, Giampiero
Ficorella, Corrado
CANCERS, 2020, 12 (05)

← 1 2 3 4 5 →